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Abstract
Thyroid hormones are of crucial importance for the functioning of nearly every organ. Remarkably, disturbances of
thyroid hormone synthesis and function are among the most common endocrine disorders affecting
approximately one third of the working German population. Over the last ten years our understanding of
biosynthesis and functioning of these hormones has increased tremendously. This includes the identification of
proteins involved in thyroid hormone biosynthesis like Thox2 and Dehal where mutations in these genes are
responsible for certain degrees of hypothyroidism. One of the most important findings was the identification of a
specific transporter for triiodothyronine (T3), the monocarboxylate transporter 8 (MCT8) responsible for directed
transport of T3 into target cells and for export of thyroid hormones out of thyroid epithelial cells. Genetic
disturbances of MCT8 in patients result in a biochemical constellation of high T3 levels in combination with low or
normal TSH and thyroxine levels leading to a new syndrome of severe X-linked mental retardation. Importantly
mice lacking MCT8 presented only with a mild phenotype, indicating that compensatory mechanisms exist in mice.
Moreover, it has become clear that not only genomic actions of T3 exist. T3 is also capable to activate adhesion
receptors and it signals via activation of PI3K and MAPK pathways. Most recently, thyroid hormone derivatives were
identified, the thyronamines which are decarboxylated thyroid hormones initiating physiological actions like
lowering body temperature and heart rate, thereby acting in opposite direction to the classical thyroid hormones.
So far it is believed that thyronamines function via the activation of a G-protein coupled receptor, TAAR1. The
objective of this review is to summarise the recent findings in thyroid hormone synthesis and action and to
discuss their implications for diagnosis of thyroid disease and for treatment of patients.
Introduction
Health consequences of disturbed thyroid
hormone action
Thyroid hormones are of significant importance for reg-
ular functioning of almost all body organs. Thyroxine
(T4) is the main hormone released from the thyroid
gland and it is transformed into biologically active
3’,3,5-triiodothyronine (T3) via 5’-deiodinases of thyroid
hormone target cells [1]. For thyroid hormone synthesis,
sufficient supply of the thyroid gland with essential
micronutrients such as iodine and selenium is crucial.
The most important target tissues of thyroid hor-
mones are the central nervous system, the cardiovascu-
lar system and the skeleton. Moreover, due to the
increasing incidence of obesity worldwide, thyroid hor-
mone action in adipose tissue has re-gained increasing
interest for understanding energy homeostasis [2].
Disturbance of thyroid hormone synthesis and thyroid
hormone actions, further referred to as thyroid disor-
ders, are among the most common endocrine afflictions
and they require special attention in specific life phases.
For instance, undiagnosed hypothyroidism during preg-
nancy will lead to irreparable central nervous system
(CNS) defects in the newborn because the development
of the child in utero is critically affected by the mother’s
thyroid status [3]. Therefore and to avoid fatal conse-
quences of a lack of thyroid hormone synthesis after
birth, eventually leading to severe mental retardation,
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thyroid stimulating hormone (TSH)-screening of new-
borns [4] was implemented in Germany and in other
countries. In action since the late 1970s and with a clear
improvement in those areas of the world where TSH-
screening was first introduced, a marked decrease in
cretinism was observed.
Thyroid hormone (TH) action serves important regu-
latory functions throughout all phases of life. Disturbed
TH action is linked with major health problems espe-
cially in critical life phases such as development, disease
or ageing. Thus, lack of TH action in the adult brain
causes impaired neuro-cognitive function and psychia-
tric states such as severe depression and dementia [5].
Not only hypothyroidism but also hyperthyroidism
affects the CNS and frequently results in agitation,
increased irritability and dysregulation of body tempera-
ture. There is ample epidemiological evidence that both,
hyper- and hypothyroidism confer an increased risk for
cardiovascular morbidity (e.g. arrhythmia, heart failure
and stroke) and mortality. Moreover, thyroid disorders
affect maturation and turnover rates of bone. For exam-
ple, children with hyperthyroidism show advanced bone
age, and post-menopausal women with thyrotoxicosis
are at risk for osteoporosis. Furthermore, adiposity is
associated with altered levels of measurable thyroid
function parameters, whereby it is not known however
whether the obesity state influences the set-point for
thyroid function parameters or vice versa. Besides the
common health issues, life threatening conditions may
either arise from severely disturbed thyroid hormone
action or are accompanied by altered thyroid hormone
action. These include e.g. thyroid storm with a mortality
of more than 30%, which at present can only be diag-
nosed on clinical grounds since measurement of thyroid
hormone levels is not useful and may be identical to
those in patients with uncomplicated thyrotoxicosis or
the non-thyroid illness syndrome in intensive care
patients with e.g. sepsis.
Health-economical dimensions of thyroid disorders are
shown most plainly by the example of latent hypothyr-
oidism which is evident in about 20% of all individuals
at the age of 60-79 years, with higher incidences in
women than in men [6]. On top of this, an increase in
the number of patients with thyroid disorders is
expected in the future. Possible causes are anthropo-
genic in origin and are represented by a variety of envir-
onmental substances, so-called endocrine disruptors
such as estrogen-derivates and PBCBs, that affect the
endocrine system at large including the thyroid gland
and thyroid hormone actions [7].
Furthermore, classical epidemiology on large cohorts
(SHIP and KORA) has underlined that manifest and
even more so, subclinical thyroid disorders are often
associated with other, quite frequently occurring
pathophysiological processes [8,9]. These include, but
are not limited to left-ventricular hypertrophy, athero-
sclerosis with increased risk for stroke and coronary
heart disease, disorders in lipid metabolism, osteoporosis
and neurodegenerative diseases. However, subclinical
hyperthyroidism was found not to be associated with e.
g. changes in blood pressure in the SHIP cohort study
[9] although serum TSH levels in the upper reference
range were indicative of endothelial dysfunction [10],
highlighting the necessity of further investigations aim-
ing at a better definition of the healthy thyroid state.
New aspects of thyroid hormone synthesis
A number of molecular causes of thyroid dysgenesis,
accounting for approx. 80% of cases suffering from con-
genital hypothyroidism (CH), have been identified over
the last few years and were shown to include mutations
in transcription factors important for thyroid develop-
ment such as Pax8, Nkx2.1, FoxE1, and HoxA3[11].
Mutations in these genes often also lead to developmen-
tal dysfunction in organs other than the thyroid, thereby
affecting the lung and the central nervous system
(Nkx2.1) [12], or the kidney (PAX8) [13]. However, only
about 5% of these genetic defects could account for the
pathogenesis of thyroid dysgenesis [14]. Therefore, non-
classical mechanisms involving epigenetic regulation are
to be considered in future as modulators of gene expres-
sion during development of the thyroid.
In addition, genetic defects have been detected in all
those genes bearing an essential role in the biosynthesis
of thyroid hormones (approx. 10 to 15% of CH cases).
These include the gene for the prohormone thyroglobu-
lin (Tg) itself [15]; the thyroid stimulating hormone
receptor (TSHR) [16], and the thyroid peroxidase (TPO)
[17]; as well as genes relevant for iodide transport, i.e.
the sodium-iodide symporter (NIS) [18] at the basolat-
eral and Pendrin[19] at the apical pole of thyroid epithe-
lial cells. Furthermore, the gene products of Dehal[20]
and Thox2[21] as well as inactivating and activating
mutations of the Gs alpha gene [22] have been added to
the growing list of candidate proteins with important
thyroid-specific functions. Recently, potassium channel
subunits Kcnq1 and Kcne2 were found to be crucial for
TSH-stimulated thyroid hormone biosynthesis. Mice
lacking Kcne2 suffer from impaired iodide uptake into
the thyroid gland and exhibit signs of hypothyroidism
[23].
A more profound understanding of thyroid hormone
biosynthesis has also led to a clearer view on the mole-
cular regulation of the thyroid gland and has increased
our knowledge about the differentiated state of thyroid
epithelial cells. In this context, novel players have been
identified, which are important for the maintenance of
thyroid physiology, i.e. molybdenum-dependent enzymes
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with important functions in the oxidative system of
thyrocytes [24] and molecules that play a role in thyro-
globulin processing for thyroid hormone liberation and
release from the thyroid gland (megalin and cysteine
cathepsins) [25-27].
Many of these players have been known for long, but
it was only recently that the impact of mutations in
thyroid-specific genes for thyroid physiology was set
into context for a clearer depiction of the interactions
and cross-relations between the many molecules and
pathways relevant for thyroid biology. The regulation
governing the functions of thyroid-specific proteins and
their precise roles in the etiology of thyroid disorders
will enable us to understand their mechanisms of action
in detail and will advance our knowledge on the mole-
cular biology of the thyroid gland.
Novel concepts of transmembrane and
intracellular thyroid hormone actions
Previous textbook knowledge of thyroid hormone entry
into cells included a diffusion-based passive transmem-
brane passage for thyroid hormones which are lipophilic
but charged molecules. However, an eye-opening revela-
tion was the identification of the MCT8 transporter
(SLC16A2) that selectively enables T3 transport into tar-
get cells [28]. This important finding explained at the
molecular level the phenotype of severe X-linked mental
retardation and disrupted locomotor development of
patients with the Allan Herndon Dudley (AHD) syn-
drome, already described in the 1940s. These patients
carry a defect in the MCT8 transporter, which explains
why T3 does not reach all of its target cells in sufficient
quantities during development. At the same time AHD
patients show highly elevated serum T3 levels with unal-
tered to elevated TSH contradicting the “normal feed-
back scenario”. Thus it needs to be investigated further
whether the abnormally high T3 levels in conditions of
MCT8 defects that are linked with normal to slightly
elevated TSH levels may cause thyrotoxic effects in TH
target tissues other than the central nervous system
[29]. However this clinical observation prompted thyroi-
dologists to question the classical views on thyroid regu-
lation. Subsequently, other TH transporter candidates
have been identified (e.g. Oatp14, Lat1, Lat2, Mct10) in
mice and require functional characterization [30-33]. It
will be important in future to not only identify the tis-
sue distribution patterns of TH transporters but more
so, to clarify their potential contributions to the intracel-
lular compartmentalisation of TH so that a clearer pic-
ture is gained on the sub-cellular gradients of TH and
how specific compartments within cells, besides the
nucleus, are supplied with TH in order to contribute or
to withstand non-classical TH actions. Further TH
transporters are eagerly awaited to be defined (Figure 1).
Another unexpected finding of recent research pro-
jects was the identification of thyroid hormone deriva-
tives, the so-called thyronamines [34]. These are
decarboxylated thyroid hormones that exert effects with
kinetics different from those of thyroid hormone
mediated actions and principally counter-acting them
(so called “cool thyroid hormones”). Most obvious
effects of thyronamines are observed in decreased heart
rates and in negative regulation of body temperature.
Thyronamines display their effects via activating a new
subfamily of G-protein-coupled receptors (GPCRs), the
trace amine associated receptors (TAARs) [35-37].
Because of their central roles in signalling resulting in a
multitude of regulatory effects on almost all biological
processes, GPCRs are interesting targets for pharmaco-
logical intervention [38]. Hence, the development of
new therapeutic agents for regulation of heart beat fre-
quency and of body temperature is now discussed in
light of emergency treatments of stroke or acute myo-
cardial infarction. Moreover, thyronamine-based thera-
pies are expected to enter intensive care medical
treatments.
Furthermore several lines of evidence suggest that in
addition to the classic nuclear thyroid hormone action,
rapid plasma membrane-initiated effects of thyroid hor-
mones exist. Signalling via adhesion receptors (aνb3
integrins) and activation of intracellular PI-3 kinase and
mitogen activated protein (MAP) kinase pathways have
been proposed to account for these effects [39-41]. The
precise mechanisms and the physiological implications
of non-classical TH actions however remain elusive.
Besides the classic hormones T4 and T3 new data
demonstrate that the rare thyroid hormone metabolite
3,5-T2 is effective in the prevention of high fat diet-
induced adiposity and prevents hepatic steatosis, how-
ever, without exerting the severe side effects on the car-
diac system that have been observed with T3-based
treatments [42] . The vital importance of thyroid hor-
mones for regulation of thermogenesis and for mainte-
nance of the homeostasis of the mitochondrial energy
metabolism has long been established. However, the
functional interactions between the activities of uncou-
pling proteins (UCP) which are triggered by T3 and
catecholamines affecting brown adipose tissue (BAT) as
well as skeletal muscle of the adult, provide new possibi-
lities for therapeutic intervention in obesity that have
only recently become apparent [43].
Thus in the present concept of thyroid hormone
action, the cellular thyroid hormone status is defined by
thyroid hormone transporters, thyroid hormone mem-
brane receptors, thyroid hormone molecules and TAM
mediated actions (Figure 1B). It is highly likely and cor-
roborated by recent experimental results that cell type-
specificity, with respect to thyroid hormone signalling,
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differs within and in between different organs. Thereby
novel avenues are opened for refinement of the concept
of organ physiology and the role of thyroid hormone
derived signals including their cellular compartmentali-
zation. Such information will complement and add to
our current concepts of classical TH actions.
Perspectives of better understanding of TH action
Epidemiology has shown unequivocally that with age the
ratio of subclinical to clinically manifest thyroid disor-
ders increases, thus thyroid disorders are a disease of
the ageing population. In light of the demographic
changes of our societies, improvements of human health
care systems should not be limited to better manage-
ment of only cardiovascular disorders, cancer, and neu-
rodegenerative diseases. We believe that modern and
future-oriented health politics and policy making
institutions need to take an endocrine organ into
account that has been known for decades, but is still
not fully “revealed”, the thyroid gland.
The knowledge of known thyroid-specific genes, the
discovery of new genes as well as the investigations of
thyroid hormone- and thyronamine-mediated actions on
their many target tissues will entail therapeutic poten-
tials not only for the prevention and treatment of thyr-
oid disorders but importantly also for major health
problems that are, as yet, not well treatable with thyroid
hormone molecules.
Further investigations of a seemingly familiar but fre-
quently overlooked endocrine organ, the thyroid gland,
bear hopes and promises for better management of
future challenges arising from current common environ-








































Figure 1 Old and new concepts of thyroid hormone action. A: Old concept of thyroid hormone action. In former times it was assumed
that thyroid hormones are able to pass the plasma membrane by passive transport. Once in the cytosol T4 is deiodinated to T3 which exerts
genomic effects by binding to the thyroid hormone receptor (TR). After hetero-dimerization with other nuclear receptors like retinoic X receptor
(RXR), transcriptional regulation is initiated resulting in activation or inactivation of target genes. B: New concepts of thyroid hormone action.
Thyroid hormones enter a target cell via specific transporters, e.g. T3 uses the monocarboxylate transporter MCT8 while T4 entry is mediated by
Lat2 or Oatp14. Moreover, T3 can interact with avb3 integrins to induce ERK1/2 signalling. Cytosolic T3 exerts genomic effects but can
additionally also act by non-genomic means after TR binding and activation of down-stream PI-3 kinase. Likewise, the naturally occurring
iodothyronine T2 is believed to stimulate metabolic rates via mitochondrial pathways, thereby bypassing genomic regulation. Besides thyroid
hormones, derivatives like the thyronamines T1AM or T0AM, modulate the action of T3, e.g. counter-acting its effects in certain target cells.
Thyronamines (TAMs) bind to and activate G-protein coupled receptors (GPCRs) of the trace amine associated receptor (TAAR) family. So far, it is
only known that TAAR1 is activated by TAMs and signals via adenylylcyclase (AC) activation with subsequent rise of cAMP levels. However other
GPCRs are likely targets for thyroid hormone derivatives.
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